Selective positive allosteric modulators of A4B2 nicotinic receptors
Active Project Grant Awarded Last action
- Award ID
- R01DA059985
- Recipient
-
Northeastern University UEI HLTMVS2JZBS6
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,862,113
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 47% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
Description
- Abstract
- Tobacco addiction remains a leading cause of disease and death worldwide, and an increasing number of never- smokers are being exposed to nicotine via E-cigarettes. However, the role of specific nicotinic acetylcholine receptors (NACHR) in nicotine's behavioral effects remains poorly understood because of the availability of very few subtype-selective probes, which limit drug development potential. Thus, this proposal aims to develop novel probes to better understand the function of the different Α4Β2 subtypes, which have been proposed to underlie behaviors characteristic of nicotine dependence. The Α4Β2 NACHR subtypes exhibit two distinct isoforms: Α42Β23, which has a high affinity for acetylcholine and nicotine, and Α43Β22 NACHR, which has a lower affinity for acetylcholine and nicotine. Our recent findings have suggested that probes selectively targeting the high sensitivity Α42Β23 nachrs may provide a novel, previously undefined understanding of nicotine's behavioral and pharmacological actions. Thus, these studies will develop and optimize novel positive allosteric modulators (PAMS) of the high sensitivity Α42Β23 nachrs. Specific aim 1 will begin by focusing on the synthesis of novel analogs of desformylflustrabromine (DFBR) and GAT2802 to derive an improved pharmacological profile. Specific aim 2 will involve in vitro characterization of novel probes from both structural classes as Α42Β3 NACHR-selective PAMS. Thereafter, specific aim 3 studies will evaluate adme/PK profiling of key Α42Β23 PAMS to eliminate potential liabilities and identify probes with suitable drug-like properties. Finally, in specific aim 4, the most promising probes will be tested for their efficacy in inducing behaviors characteristic of nicotine's 42 NACHR actions in adult male and female mice. Taken together, these studies will develop and validate novel HS-selective Α42Β23 PAM probes to better understand the pharmacological effects of Α4Β2 nachrs in behaviors characteristic of nicotine's actions, which may thereby lead to future therapeutic implications.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $674,338 | |
| Amendment | $700,679 | |
| Amendment | $743,548 | |
| Original award | $743,548 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The University Of Texas At Tyler | $160,907 | |
| Virginia Commonwealth University | $119,404 | |
| University Of California Irvine | $110,122 | |
| Virginia Commonwealth University | $117,232 | |
| The University Of Texas At Tyler | $164,177 | |
| University Of California Irvine | $108,497 | |
| University Of California Irvine | $55,918 | |
| The University Of Texas At Tyler | $203,759 |
Quick answers
Who received award R01DA059985?
R01DA059985 was awarded to Northeastern University by National Institute on Drug Abuse (National Institutes of Health) on August 1, 2024.
How much is award R01DA059985 worth?
$2,862,113 has been obligated on R01DA059985.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award